Devinder Ubhi

Devinder Ubhi is a Director at IGM Biosciences, Inc., where they currently lead a growing Protein Analytics and Characterization group focused on developing innovative IgM antibodies. With over seven years of experience in protein characterization, analytics, and FDA regulatory processes, Devinder played key roles in obtaining BLA approval for AndexXa® at Portola Pharmaceuticals and IND approval for IGM-8444 at IGM Biosciences. They completed a Ph.D. in Cell and Molecular Biology at the University of Texas at Austin, where they also published research on fungal enzymes and mentored undergraduate researchers. Prior to their current role, Devinder held various scientific positions in both startups and larger pharmaceutical companies, contributing significantly to drug development processes.